In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019
Microbial Drug Resistance · 01.08.2023 · 29 (8) · 360-370
DOI: 10.1089/mdr.2022.0279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Drug Resistance, online erschienen am 31.07.2023. Verfasst von Mark G Wise und 6 weiteren Autor:innen. Beteiligte Einrichtung: IHMA, Schaumburg, Illinois, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Negative Bacteria. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We examined the in vitro susceptibility of meropenem-nonsusceptible Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii complex isolates from five consecutive annual SIDERO-WT surveillance studies (2014–2019) to cefiderocol and comparator agents in the context of their carbapenemase carriage. 1,003 Enterobacterales, 1,758 P. aeruginosa , and 2,809 A. baumannii complex isolates from North America and Europe that were meropenem nonsusceptible (CLSI M100, 2022) were molecularly characterized for β-lactamase content by PCR followed by Sanger sequencing or by whole genome sequencing. Among Enterobacterales, 91.5% of metallo-β-lactamase (MBL)–producing, 98.4% of KPC-producing, 97.3% of OXA-48 group–producing, and 98.7% of carbapenemase-negative, meropenem-nonsusceptible isolates were cefiderocol susceptible (MIC ≤4 mg/L). Among P. aeruginosa , 100% of MBL-producing, 100% of GES carbapenemase-producing, and 99.8% of carbapenemase-negative, meropenem-nonsusceptible isolates were cefiderocol susceptible (MIC ≤4 mg/L). Among A. baumannii complex, 60.0% of MBL-producing, 95.6% of OXA-23 group-producing, 89.5% of OXA-24 group-producing, 100% of OXA-58 group-producing, and 95.5% of carbapenemase-negative, meropenem-nonsusceptible isolates were cefiderocol susceptible (MIC ≤4 mg/L). Cefiderocol was inactive against A. baumannii complex isolates carrying a PER or VEB β-lactamase ( n = 103; 15.5% susceptible). Ceftazidime–avibactam and ceftolozane–tazobactam were inactive against MBL-carrying and A. baumannii complex isolates; ceftolozane–tazobactam was also inactive against serine carbapenemase–carrying Enterobacterales and P. aeruginosa . In summary, cefiderocol was highly active in vitro against Gram-negative isolates carrying MBLs and serine carbapenemases, as well as carbapenemase-negative, meropenem-nonsusceptible isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IHMA, Schaumburg, Illinois, USA.
- Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
- Laboratory for Drug Discovery and Disease Research and Shionogi & Co., Ltd., Osaka, Japan.
- Research Planning Department, Shionogi & Co., Ltd., Osaka, Japan.
- Infectious Disease Drug Development Consulting, LLC, Easton, Connecticut, USA.
Zitieren
APA
Wise, M. G., Karlowsky, J. A., Hackel, M. A., Takemura, M., Yamano, Y., Echols, R., & Sahm, D. F. (2023). In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019. Microbial Drug Resistance, 29(8), 360-370. https://doi.org/10.1089/mdr.2022.0279
Vancouver
Wise MG, Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, et al. In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019. Microbial Drug Resistance. 2023;29(8):360-370. doi:10.1089/mdr.2022.0279
BibTeX
@article{Wise2023,
author = {Wise, Mark G and Karlowsky, James A and Hackel, Meredith A and Takemura, Miki and Yamano, Yoshinori and Echols, Roger and Sahm, Daniel F},
title = {In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019},
journal = {Microbial Drug Resistance},
year = {2023},
volume = {29},
number = {8},
pages = {360--370},
doi = {10.1089/mdr.2022.0279}
}
EUVIMED